吉西他滨联合顺铂治疗23例晚期非小细胞肺癌

目的研究国产吉西他滨联合顺铂治疗非小细胞肺癌的疗效及毒性反应。方法经病理组织学或细胞学证实的23例非小细胞肺癌患者于第1天和第8天给予吉西他滨1000mg/m2静滴,第1天给予顺铂(DDP)70mg/m2静滴,4周为1周期。结果23例中无1例完全缓解(CR),部分缓解(PR)为47%(11/23)。结论国产吉西他滨联合顺铂对晚期非小细胞肺癌有较好的疗效,且毒副反应可接受。

Objective To evaluate the efficacy, toxicity and side effects of the combination of gemcitabine and cisplatin in the treatment on the patients with non-small-cell lung cancer （NSCLC）. Methods The 23 patients with NSCLC diagnosed by pathology or cytology were enrolled into the study. The patients received gemcitabine 1000mg/m^2 on the first and eighth day and cisplatin 70 mg/m^2 on the first day, of 28-day cycle （4-week regiment）. Results The complete response rate was zero, and partial response rate was 47%. Conclusion The combination of gemcitabine and cisplatin is an effective and tolerable in the treatment of NSCLC.